PMID- 29293033
OWN - NLM
STAT- MEDLINE
DCOM- 20181121
LR  - 20181121
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 28
IP  - 5
DP  - 2018 Sep
TI  - Early prediction for over two years efficacy of the first biologic agent for 
      polyarticular juvenile idiopathic arthritis: A multi-institutional study in 
      Japan.
PG  - 826-831
LID - 10.1080/14397595.2017.1415628 [doi]
AB  - OBJECTIVE: To estimate target of treatment for long-term efficacy of the first 
      biologic agent used to treat polyarticular juvenile idiopathic arthritis (pJIA). 
      METHODS: A retrospective cohort of patients with pJIA treated at six medical 
      institutions in Japan between 1 March 2005 and 31 October 2014 was identified. 
      The patients were divided by 2-year treatment periods with the first biologic 
      agent into continuous treatment group and switching group. Three markers were 
      examined: matrix metalloproteinase-3 (MMP-3), erythrocyte sedimentation rate 
      (ESR), and disease activity score (DAS) 28-ESR. RESULTS: Thirty-two pJIA patients 
      (8 boys, 24 girls) from 43 recruited patients were included in this study. The 
      treatment periods with the first biologic agent in continuous treatment group (24 
      patients, 75%) was 40 months (median, range 24-119) and switching group (8 
      patients; 25%) was 9.5 months (median, 6-18). Markers [odds ratio (95% confidence 
      interval)] at 3 months were MMP-3 [1.02 (0.99-1.05), p = .219], ESR [1.00 
      (0.78-1.30), p = .998], and DAS28-ESR [13.9 (2.08-409.82), p = .035]. The cut-off 
      point for DAS28-ESR at 3 months to distinguish the two groups was 2.49 
      (sensitivity, 87.5%; specificity, 87.5%). CONCLUSION: DAS28-ESR of 2.49 at 3 
      months after initiating the first biologic agent can be a target of sustained 
      treatment in pJIA patients.
FAU - Kubota, Tomohiro
AU  - Kubota T
AD  - a Department of Pediatrics, Graduate School of Medical and Dental Sciences , 
      Kagoshima University , Kagoshima , Japan.
AD  - b Department of Pediatrics , Kagoshima University Hospital , Kagoshima , Japan.
FAU - Takei, Syuji
AU  - Takei S
AD  - b Department of Pediatrics , Kagoshima University Hospital , Kagoshima , Japan.
FAU - Shimizu, Masaki
AU  - Shimizu M
AD  - c Department of Pediatrics, School of Medicine , Institute of Medical, 
      Pharmaceutical, and Health Sciences, Kanazawa University , Kanazawa , Japan.
FAU - Yasumura, Junko
AU  - Yasumura J
AD  - d Department of Pediatrics , Hiroshima University Graduate School of Biomedical 
      and Health Sciences , Hiroshima , Japan.
FAU - Nakagishi, Yasuo
AU  - Nakagishi Y
AD  - e Department of Pediatric Rheumatology , Hyogo Prefectural Kobe Children's 
      Hospital , Kobe , Japan.
FAU - Kizawa, Toshitaka
AU  - Kizawa T
AD  - f Department of Pediatrics , Sapporo Medical University School of Medicine , 
      Sapporo , Japan.
FAU - Yashiro, Masato
AU  - Yashiro M
AD  - g Department of Pediatrics , Okayama University Graduate School of Medicine, 
      Dentistry and Pharmaceutical Sciences , Okayama , Japan.
FAU - Wakiguchi, Hiroyuki
AU  - Wakiguchi H
AD  - b Department of Pediatrics , Kagoshima University Hospital , Kagoshima , Japan.
FAU - Yamasaki, Yuichi
AU  - Yamasaki Y
AD  - b Department of Pediatrics , Kagoshima University Hospital , Kagoshima , Japan.
FAU - Kawano, Yoshifumi
AU  - Kawano Y
AD  - a Department of Pediatrics, Graduate School of Medical and Dental Sciences , 
      Kagoshima University , Kagoshima , Japan.
AD  - b Department of Pediatrics , Kagoshima University Hospital , Kagoshima , Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180102
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Juvenile/blood/*drug therapy
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
OTO - NOTNLM
OT  - Biologic agents
OT  - DAS28-ESR
OT  - juvenile idiopathic arthritis
OT  - polyarticular type
OT  - treat to target
EDAT- 2018/01/03 06:00
MHDA- 2018/11/22 06:00
CRDT- 2018/01/03 06:00
PHST- 2018/01/03 06:00 [pubmed]
PHST- 2018/11/22 06:00 [medline]
PHST- 2018/01/03 06:00 [entrez]
AID - 10.1080/14397595.2017.1415628 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2018 Sep;28(5):826-831. doi: 10.1080/14397595.2017.1415628. Epub 
      2018 Jan 2.